Showing results (1531-1540 of 2,517) with videos related to
Sort By:
Pageof 252
Journal of the International AIDS Society|November 15, 2014
Darunavir-based dual therapy in HIV experienced patientsGaetana Sterrantino, Mauro Zaccarelli, Antonio Di Biagio, et al.Journal of the International AIDS Society|November 15, 2014
The efficacy, pharmacokinetics, safety and cardiovascular risks of switching nevirapine to rilpivirine in HIV-1 patients: the RPV switch studyCasper Rokx, Maren Blonk, Annelies Verbon, et al.Journal of the International AIDS Society|November 15, 2014
Boosted lopinavir vs boosted atazanavir in patients failing a NNRTI first line regimen in an urban clinic in KampalaEva Laker, Ivan Mambule, Damalie Nalwanga, et al.Journal of the International AIDS Society|November 15, 2014
Switching to nevirapine-based regimens after undetectable viral load is not associated with increased risk of discontinuation due to toxicityPatricia Patterson, Eugenia Socías, Daniel Pryluka, et al.Journal of the International AIDS Society|November 15, 2014
Durability of first antiretroviral treatment in HIV chronically infected patients: why change and what are the outcomes?Patricia Moniz, Filipa Alçada, Susana Peres, et al.Journal of the International AIDS Society|November 15, 2014
Switching from an EFV-based STR to a RPV-based STR is effective, safe and improves HIV patients health statusFranco Maggiolo, Sergio Di Matteo, Giacomo Bruno, et al.Journal of the International AIDS Society|November 15, 2014
Use of maraviroc in patients with undetectable viral load: efficacy, tolerance and predictors of viral response in MARAVIROC-cohort studyMaría Jesús Pérez Elías, David Arroyo, Alberto Diaz, et al.Journal of the International AIDS Society|November 15, 2014
Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT studyVincenzo Spagnuolo, Laura Galli, Alba Bigoloni, et al.Journal of the International AIDS Society|November 15, 2014
Simplification to atazanavir/ritonavir+lamivudine in virologically suppressed HIV-infected patients: 24-weeks interim analysis from ATLAS-M trialMassimiliano Fabbiani, Simona Di Giambenedetto, Eugenia Quiros-Roldan, et al.Journal of the International AIDS Society|November 15, 2014
Monotherapy with darunavir/ritonavir is effective and safe in clinical practiceJuan Pasquau, Luis López-Cortés, Maria Isabel Mayorga, et al.Pageof 252